Defence Therapeutics Inc.
DTCFF
$0.6447
-$0.3517-35.30%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 70.20% | -58.48% | -92.56% | -83.30% | -72.56% |
| Total Depreciation and Amortization | 656.31% | 230.96% | 504.90% | 179.17% | 9.57% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -92.09% | 1,495.18% | 1,803.20% | 1,446.65% | 2,174.03% |
| Change in Net Operating Assets | 418.35% | 260.16% | 214.55% | 883.91% | -153.24% |
| Cash from Operations | 62.47% | 81.72% | 62.39% | 34.23% | 19.88% |
| Capital Expenditure | -1,618.82% | -174.11% | -211.13% | -272.77% | 81.03% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -1,462.35% | -174.11% | -211.13% | -272.77% | 81.03% |
| Total Debt Issued | -- | -97.24% | -97.88% | -100.00% | -100.00% |
| Total Debt Repaid | -1,076.19% | -195.24% | -- | -162.90% | -- |
| Issuance of Common Stock | -67.33% | -79.18% | -82.23% | -41.87% | 286.79% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 57.16% | 76.87% | 79.03% | 47.87% | -34.49% |
| Cash from Financing | -69.76% | -84.56% | -86.44% | -58.52% | 66.50% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -118.33% | -117.79% | -176.75% | -213.73% | 141.24% |